(Q38185017)

30 August 2017

mTOR controls kidney epithelia in health and disease (English)

1 reference

30 August 2017

1

Florian Grahammer

0 references

author name string

Nicola Wanner

series ordinal

2

1 reference

PubMed ID

24493874

30 August 2017

Tobias B Huber

series ordinal

3

1 reference

PubMed ID

24493874

30 August 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

Nephrology Dialysis Transplantation

30 August 2017

1 reference

30 August 2017

29 Suppl 1

1 reference

30 August 2017

i9-i18

1 reference

Estimating the financial cost of chronic kidney disease to the NHS in England

30 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Rapalogs and mTOR inhibitors as anti-aging therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Amino acid signalling upstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR is a key modulator of ageing and age-related disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR signaling in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

How many ways can a podocyte die?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Podocyte regeneration: who can become a podocyte?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Increased tubular proliferation as an adaptive response to glomerular albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The spectrum of podocytopathies: a unifying view of glomerular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Growth-dependent podocyte failure causes glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Mammalian target of rapamycin signaling in the podocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Significance and management of proteinuria in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The role of the mammalian target of rapamycin (mTOR) in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The Notch pathway in podocytes plays a role in the development of glomerular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Old friends form alliance against podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The role of the Atg1/ULK1 complex in autophagy regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Inhibition of MTOR disrupts autophagic flux in podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Recruitment of podocytes from glomerular parietal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Rapamycin-induced phosphaturia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mTOR complex-2 activates ENaC by phosphorylating SGK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The physiological impact of the serum and glucocorticoid-inducible kinase SGK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

mSIN1 protein mediates SGK1 protein interaction with mTORC2 protein complex and is required for selective activation of the epithelial sodium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Histopathology of chronic rejection in a nonhuman primate model of vascularized composite allotransplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Tuberous sclerosis complex: neurological, renal and pulmonary manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Clinical and molecular insights into tuberous sclerosis complex renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Emerging treatments in the management of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Clinical practice. Autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Primary cilia regulate mTORC1 activity and cell size through Lkb1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT491

21 January 2018

Identifiers

DOI

10.1093/NDT/GFT491

1 reference

30 August 2017

1 reference

PubMed ID

24493874